Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5436212 | 1.00 | CYP1A2 (0.46) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL5434156 | 1.00 | CYP1A2 (0.46) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL5434152 | 1.00 | CYP1A2 (0.46) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL5437250 | 1.00 | CYP1A2 (0.46) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL5434162 | 1.00 | CYP1A2 (0.46) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL5437247 | 1.00 | CYP1A2 (0.46) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL1643333 | 0.95 | CYP1A2 (0.46) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL7297015 | 0.93 | CYP1A2 (0.49) | CYP1A2USP2ALDH1A1LMNATSHR | |
| Hydrochloric Acid SCHEMBL6379074 | 0.93 | CYP1A2 (0.44) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL5434578 | 0.89 | CYP1A2 (0.41) | CYP1A2USP2ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921835-B2 | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents | WARNER LAMBERT COMPANY (US) | 2005-07-26 | — | — | US | claimed |
| US-20030220397-A1 | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2003-11-27 | — | — | US | claimed |
| US-20030212133-A1 | Gabapentin analogues for sleep disorders | BRYANS JUSTIN STEPHEN (GB) | 2003-11-13 | — | — | US | claimed |
| CN-1436075-A | Gabapentin analogues for sleep disorders | WARNER LAMBERT CO (US) | 2003-08-13 | — | — | CN | claimed |
| CN-101283995-A | Different pharmaceutical uses alpha2delta ligands | WARNER LAMBERT CO (US) | 2008-10-15 | — | — | CN | disclosed |
| CN-100367946-C | Gabapentin analogs for the treatment of fibromyalgia and other disorders | WARNER LAMBERT CO (US) | 2008-02-13 | — | — | CN | disclosed |
| US-20070293570-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070276039-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY LLC (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070213401-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY LLC (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070161706-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY LLC (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161707-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY LLC (US) | 2007-07-12 | — | — | US | disclosed |
| US-7141606-B2 | Gabapentin analogues for sleep disorders | WARNER-LAMBERT COMPANY (US) | 2006-11-28 | — | — | US | disclosed |
| US-20040132636-A1 | Pharmaceutical uses for alpha2delta ligands | DOOLEY DAVID JAMES (US) | 2004-07-08 | — | — | US | disclosed |
| US-20030220397-A1 | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2003-11-27 | — | — | US | disclosed |
| US-20030212133-A1 | Gabapentin analogues for sleep disorders | BRYANS JUSTIN STEPHEN (GB) | 2003-11-13 | — | — | US | disclosed |
| US-20030199567-A1 | Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2 | TAYLOR CHARLES PRICE (US) | 2003-10-23 | — | — | US | disclosed |
| US-6635673-B1 | 1-Aminomethyl-3,4-dimethyl-cyclopentyl acetic acid; epilepsy; neurodegenerative, neuropathological and gastrointestinal disorders; depression, anxiety, panic, pain | WARNER-LAMBERT COMPANY | 2003-10-21 | — | — | US | disclosed |
| CN-1436075-A | Gabapentin analogues for sleep disorders | WARNER LAMBERT CO (US) | 2003-08-13 | — | — | CN | disclosed |
| EP-1032555-A1 | CYCLIC AMINO ACIDS AND DERIVATIVES THEREOF USEFUL AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999021824-A1 | CYCLIC AMINO ACIDS AND DERIVATIVES THEREOF USEFUL AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213401-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | CYP1A2 347/4885USP2 4327/4885ALDH1A1 268/4885 |
| US-20030220397-A1 | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents | APC, VIP, NPSR1 | CYP1A2 3494/4885USP2 4204/4885ALDH1A1 3481/4885 |
| US-20070293570-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | CYP1A2 347/4885USP2 4327/4885ALDH1A1 268/4885 |
| US-20030199567-A1 | Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2 | CACNG2, GABRB2, CACNG4 | CYP1A2 534/4885USP2 1465/4885ALDH1A1 543/4885 |
| US-20070161707-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | CYP1A2 347/4885USP2 4327/4885ALDH1A1 268/4885 |
| US-20070276039-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | CYP1A2 347/4885USP2 4327/4885ALDH1A1 268/4885 |
| US-20070161706-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | CYP1A2 347/4885USP2 4327/4885ALDH1A1 268/4885 |
| US-20030212133-A1 | Gabapentin analogues for sleep disorders | GABRA1, SLC6A1, GABRB1 | CYP1A2 866/4885USP2 4432/4885ALDH1A1 757/4885 |
| US-20040132636-A1 | Pharmaceutical uses for alpha2delta ligands | ADRA1D, OPRD1, ADRA1A | CYP1A2 438/4885USP2 4293/4885ALDH1A1 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.